Swixx BioPharma
Modern Medicines for All

Announcement

SWIXX WELCOMES MARTIN DEWHURST AS INDEPENDENT DIRECTOR

Baar, Switzerland, July 22nd, 2026 – Swixx Biopharma AG, a leading provider of rest-of-world commercialization services, today announced the appointment of Martin Dewhurst as an independent director. Following the completion of the strategic investment by SK Capital Partners and Bain Capital Life Sciences, the Board now brings together representatives of the company's new lead investors, founders and independent board members. This combination of perspectives and experience will support Swixx's continued development as a leading multi-regional partner for biopharmaceutical companies.

Martin Dewhurst brings more than three decades of international healthcare experience spanning strategy, investing, corporate governance and healthcare innovation. Following a 30-year career at McKinsey & Company, he has built a broad portfolio of leadership roles across healthcare services, diagnostics, medical technology and biopharmaceutical innovation. He currently serves on the boards of several healthcare and life sciences companies, including Unilabs, Distalmotion, Turn Therapeutics and Cytovation.

Aaron Davenport, Managing Director at SK Capital Partners and Swixx Biopharma Board Chairman, said: “Swixx has built a highly differentiated platform with a trusted reputation among biopharmaceutical partners, and we are committed to supporting the company as it continues to expand its geographic footprint and broaden access to medicines for patients. We are pleased to welcome Martin Dewhurst as an independent director. His experience across investing, governance and healthcare innovation will be a valuable asset as Swixx continues its next phase of growth.”

Jean-Michel Lespinasse, Chief Executive Officer of Swixx Biopharma, added, “We are delighted to welcome Martin and look forward to benefiting from his experience and insights to help us continue to serve partners and patients around the world.”

Martin Dewhurst, Independent Director of Swixx Biopharma, commented: “I am delighted to join Swixx at an exciting moment of continued geographic and therapeutic expansion. Swixx offers a best-in-class commercialization platform to pharma companies and biotechs looking to unlock growth and drive efficiency in markets which may not be their core strategic priority.”

Further information about Swixx Biopharma Board is available on the company website About us | Swixx BioPharma | Modern Medicines for All. For information about the strategic investment completed on June 1, 2026, please see the investment closing announcement.

About Swixx Biopharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, CNS, specialty and vaccines talent under one roof, Swixx Biopharma entered 2026 with more than 1,700 employees on board. For more information about Swixx, please visit: www.swixxbiopharma.com.

Swixx investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086